Intelligence Feed event · Equity · 2026-09-21

    Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2

    Question

    Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2

    Direct answer

    Bristol Myers Squibb demonstrated continued progress in replacing legacy revenue streams, with its growth portfolio generating 15% year-over-year growth to reach approximately 60% of total company sales in Q2. Total quarterly revenue reached $12.9 billion alongside a 153% increase in earnings per share. The biopharma company's shares have gained 17% year-to-date as the market prices in reduced exposure to patent expirations. Valuation metrics continue to reflect a discount relative to the broader large-cap pharmaceutical peer group.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/bristol-myers-squibb-growth-portfolio-reaches-60-of-revenue-in-q2-bb4951

    EQUITY
    Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2
    Bristol Myers Squibb demonstrated continued progress in replacing legacy revenue streams, with its growth portfolio generating 15% year-over-year growth to reach approximately 60% of total company sales in Q2. Total quarterly revenue reached $12.9 billion alongside a 153% increase in earnings per share. The biopharma company's shares have gained 17% year-to-date as the market prices in reduced exposure to patent expirations. Valuation metrics continue to reflect a discount relative to the broader large-cap pharmaceutical peer group.
    BMYABBV
    Impact
    67
    SEP 21
    SIG
    85%
    BMYABBV
    Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2
    Bristol Myers Squibb demonstrated continued progress in replacing legacy revenue streams, with its growth portfolio generating 15% year-over-year growth to reach approximately 60% of total company sales in Q2. Total quarterly revenue reached $12.9 billion alongside a 153% increase in earnings per share. The biopharma company's shares have gained 17% year-to-date as the market prices in reduced exposure to patent expirations. Valuation metrics continue to reflect a discount relative to the broader large-cap pharmaceutical peer group.
    → Revenue mix shift toward newer therapies directly mitigates cash flow drag from upcoming patent expirations across BMY's $12.9B quarterly top line.
    Impact
    Bristol Myers Squibb demonstrated continued progress in replacing legacy revenue streams, with its growth portfolio generating 15% year-over-year growth to reach approximately 60% of total company sales in Q2. Total quarterly revenue reached $12.9 billion alongside a 153% increase in earnings per share. The biopharma company's shares have gained 17% year-to-date as the market prices in reduced exposure to patent expirations. Valuation metrics continue to reflect a discount relative to the broader large-cap pharmaceutical peer group.
    Affected
    BMYABBV
    Transmission
    Revenue mix shift toward newer therapies directly mitigates cash flow drag from upcoming patent expirations across BMY's $12.9B quarterly top line.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BMYoperating margin stabilization via growth drug commercializationUp1-3mQ2 revenue of $12.9B with growth portfolio reaching nearly 60% of revenue at 15% YoY growth.
    ABBVbiopharma peer valuation multiple benchmarkingWatch1-3mPeer company in large-cap biopharma space managing similar patent exclusivity transitions.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month